- Home
- TRIP vs CNTA Comparison
TRIP vs CNTA Comparison
Compare TRIP & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- CNTA
- Stock Information
- Founded
- TRIP 2000
- CNTA 2020
- Country
- TRIP United States
- CNTA United Kingdom
- Employees
- TRIP N/A
- CNTA N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- CNTA Health Care
- Exchange
- TRIP Nasdaq
- CNTA Nasdaq
- Market Cap
- TRIP 2.0B
- CNTA 2.2B
- IPO Year
- TRIP 2011
- CNTA 2021
- Fundamental
- Price
- TRIP $14.17
- CNTA $14.38
- Analyst Decision
- TRIP Hold
- CNTA Strong Buy
- Analyst Count
- TRIP 14
- CNTA 9
- Target Price
- TRIP $17.86
- CNTA $25.63
- AVG Volume (30 Days)
- TRIP 2.9M
- CNTA 1.1M
- Earning Date
- TRIP 05-07-2025
- CNTA 03-24-2025
- Dividend Yield
- TRIP N/A
- CNTA N/A
- EPS Growth
- TRIP N/A
- CNTA N/A
- EPS
- TRIP 0.04
- CNTA N/A
- Revenue
- TRIP $1,835,000,000.00
- CNTA N/A
- Revenue This Year
- TRIP $7.74
- CNTA N/A
- Revenue Next Year
- TRIP $7.49
- CNTA N/A
- P/E Ratio
- TRIP $392.35
- CNTA N/A
- Revenue Growth
- TRIP 2.63
- CNTA N/A
- 52 Week Low
- TRIP $12.93
- CNTA $7.75
- 52 Week High
- TRIP $28.64
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- TRIP 41.88
- CNTA 37.65
- Support Level
- TRIP $14.64
- CNTA $13.78
- Resistance Level
- TRIP $15.46
- CNTA $15.04
- Average True Range (ATR)
- TRIP 0.51
- CNTA 1.07
- MACD
- TRIP 0.08
- CNTA -0.24
- Stochastic Oscillator
- TRIP 38.57
- CNTA 14.93
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.